[AMGN] Amgen Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 147.55 Change: 1.19 (0.81%)
Ext. hours: Change: 0 (0%)

chart AMGN

Refresh chart

Strongest Trends Summary For AMGN

AMGN is in the long-term up 396% in 17 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company?s principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate

Fundamental Ratios
Shares Outstanding EPS10.63 EPS Growth - 4 Quarters-5.54% EPS Growth - Q/Q23.37%
EPS Growth - Y/Y-9.79% Sales Growth - 4 Quarters -2.84% Sales Growth - Q/Q-5.59% P/E15.28
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA8.28% ROE21.53% ROI9.63%
Current Ratio5.53 Quick Ratio5.11 Long Term Debt/Equity1.04 Debt Ratio0.24
Gross Margin78.78% Operating Margin33.29% Net Profit Margin27.74% Dividend Payout Ratio-34.86%
Dividend Yield
Fundamental Data
Cash From Financing Activities-1.24 B Cash From Investing Activities-952 M Cash From Operating Activities1.33 B Gross Profit4.57 B
Net Profit1.65 B Operating Profit2.08 B Total Assets71.21 B Total Current Assets37.74 B
Total Current Liabilities6.89 B Total Debt31.95 B Total Liabilities43.73 B Total Revenue5.37 B
Technical Data
High 52 week206.65 Low 52 week165 Last close194.87 Last change5.95%
RSI76.37 Average true range5.08 Beta0.85 Volume2.05 M
Simple moving average 20 days8.76% Simple moving average 50 days8.94% Simple moving average 200 days5.51%
Performance Data
Performance Week4.82% Performance Month10.25% Performance Quart15.18% Performance Half5.58%
Performance Year0.68% Performance Year-to-date0.88% Volatility daily2% Volatility weekly4.47%
Volatility monthly9.16% Volatility yearly31.75% Relative Volume183.77% Average Volume2.88 M
New High New Low

News

2020-06-02 06:00:00 | Here Are Six Dividend Stocks With Solid Payout Prospects—and a Built-In Exit Strategy

2020-06-01 09:53:01 | The Zacks Analyst Blog Highlights: Novo Nordisk, International Business Machines, Honeywell International, Amgen and S&P Global

2020-06-01 08:00:00 | Biotech ETFs Are Soaring. These Four Are Still Worth Considering.

2020-06-01 07:47:11 | Drugmakers Focus on Coronavirus Vaccine by 2020: 4 Winners

2020-05-30 11:31:03 | Why Is Amgen AMGN Down 4% Since Last Earnings Report?

2020-05-29 19:38:00 | Betting on Boeing to Fly Out of the Storm Clouds

2020-05-29 12:39:04 | Top Stock Reports for Novo Nordisk, IBM & Honeywell

2020-05-29 08:00:00 | Amgen Presents New AMG 510 Clinical Data Across Multiple Solid Tumors During ASCO20 Virtual Scientific Program

2020-05-28 17:00:00 | Amgen To Present At The Jefferies 2020 Virtual Healthcare Conference

2020-05-28 16:13:51 | Why This Event Could Clear The Deck For An Alexion Takeover: Analyst

2020-05-28 14:16:00 | Nasdaq Today: Why Alexion and Workday Stock Are Soaring

2020-05-28 09:27:00 | Alexion Stock Jumps on Signal That Fight Over Patent May End Soon

2020-05-27 15:03:58 | Hedge Funds Started Cashing Out Of Amgen, Inc. AMGN

2020-05-27 13:16:22 | As Amgen Stock Trades Near Key Support, Consider This Bullish Option Trade

2020-05-27 10:00:53 | Is Amgen Stock A Buy As It Takes A Two-Pronged Approach To Coronavirus?

2020-05-26 17:00:00 | Amgen To Webcast Investor Meeting At 56th Annual Meeting Of The American Society Of Clinical Oncology ASCO

2020-05-26 07:52:11 | Coronavirus Vaccine Development Gathers Steam: 4 Winners

2020-05-20 19:00:00 | Amgen Announces Voting Results Of Annual Meeting Of Stockholders

2020-05-19 08:03:12 | 5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up

2020-05-19 08:00:53 | Biotech Giant Amgen Is Nearing A Breakout, But Is AMGN Stock A Buy?

2020-05-18 15:37:10 | We could still see a V-Shaped recovery: Expert

2020-05-18 12:00:04 | Amgen AMGN Upgraded to Buy: What Does It Mean for the Stock?

2020-05-14 10:46:00 | Merck, Roche, Amgen Stocks React to Release of Cancer-Drug Data

2020-05-13 15:45:05 | Dow Jones Slides 1,171 Points In 3 Days After Fed Chair Speech Sharpens Recession Fear

2020-05-13 14:35:00 | Earnings season shows how fast companies have upped their digital game, says Goldman

2020-05-13 06:32:00 | Is Now Still a Good Time To Buy Amgen?

2020-05-12 13:36:05 | The Zacks Analyst Blog Highlights: Amgen, BHP, Altria, Apple and Target

2020-05-12 09:00:00 | Amgen To Present At The Bank Of America Merrill Lynch Virtual Global Healthcare Conference

2020-05-11 13:23:05 | Top Research Reports for Amgen, BHP, Altria & Others

2020-05-11 09:07:00 | Why Amgen Soared in April

2020-05-10 08:04:35 | Should You Buy Amgen Inc. NASDAQ:AMGN For Its Upcoming Dividend In 4 Days?

2020-05-08 16:24:08 | Are Biotech ETFs in Trouble as Coronavirus Dims Guidance?

2020-05-08 11:23:17 | 5 Biopharmas Where BofA Would Put Its Money To Work

2020-05-08 08:30:10 | FDA Grants Fast Track Designation for Omecamtiv Mecarbil in Heart Failure

2020-05-07 11:24:25 | Akebia Shares Climb on Positive Anemia Drug Study Results

2020-05-06 14:50:00 | These 23 companies are working on coronavirus treatments or vaccines — here’s where things stand

2020-05-06 12:01:00 | Coronavirus update: U.S. death toll tops 71,000, as Trump backs off plan to wind down pandemic task force

2020-05-06 09:00:00 | Amgen Announces Positive Top-Line Results From Otezla® apremilast Phase 3 ADVANCE Study In Mild-To-Moderate Plaque Psoriasis

2020-05-06 08:19:00 | Adaptive, Microsoft to conduct study evaluating T-cells in COVID-19 patients

2020-05-05 15:26:42 | Coronavirus U.S. death toll may hit 134k+ by early August, study reveals

2020-05-05 11:50:00 | Why Akebia Therapeutics Stock Is Crushing It Today

2020-05-05 09:00:00 | KYPROLIS® carfilzomib Patents Upheld Against Generic Manufacturer

2020-05-05 07:21:00 | Akebia's shares jump on late-stage clinical trial results for kidney disease drug

2020-05-04 17:59:35 | Cytokinetics Trading at Half High Target of $30

2020-05-04 15:12:59 | Trump expresses confidence for coronavirus vaccine ‘by the end of the year’

2020-05-04 10:15:06 | Amgen Inc. -- Moody's assigns Baa1 rating to Amgen's new sr. unsecured notes; stable outlook

2020-05-03 08:19:13 | Amgen Inc. NASDAQ:AMGN First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

2020-05-01 22:44:48 | Edited Transcript of AMGN earnings conference call or presentation 30-Apr-20 9:30pm GMT

2020-05-01 10:54:02 | Amgen AMGN Q1 Earnings Top, to Study Otezla for Coronavirus

2020-05-01 08:00:53 | Biotech Amgen Is Tackling Coronavirus From Two Sides — But Is It A Buy?